Data from FDA - Curated by EPG Health - Last updated 14 August 2018

Indication(s)

1 INDICATIONS AND USAGE Exforge HCT (amlodipine, valsartan, hydrochlorothiazide) is indicated for the treatment of hypertension, to lower blood pressure.

Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.

These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including amlodipine, hydrochlorothiazide, and the ARB class to which valsartan principally belongs.

There are no controlled trials demonstrating risk reduction with Exforge HCT. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake.

Many patients will require more than 1 drug to achieve blood pressure goals.

For specific advice on goals and management, see published guidelines, such as those of the

National High Blood Pressure Education Program 's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).

Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits.

The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly.

Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit.

Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (e.g., patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.

Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease).

These considerations may guide selection of therapy.

This fixed combination drug is not indicated for the initial therapy of hypertension [see Dosage and Administration (2)].

Exforge HCT is a combination tablet of amlodipine, a dihydropyridine calcium channel blocker (DHP CCB), valsartan, an angiotensin II receptor blocker (ARB), and hydrochlorothiazide, a thiazide diuretic.

Exforge HCT is indicated for the treatment of hypertension to lower blood pressure.

Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes, and myocardial infarctions.

(1) Not indicated for initial therapy

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Cardiovascular Metabolism Knowledge Centre

Cardiovascular Metabolism Knowledge Centre

The Cardiovascular Metabolism Knowledge Centre is an information hub providing expert insight into the management of hypertension and type 2 diabetes. This Knowledge Centre contains a wealth of scientific video content offering insights and opinion from some of the leading experts in the field.

Sleep Apnea

Sleep Apnea

Sleep apnea is a chronic condition characterised by recurrent interruptions in breathing throughout the sleep cycle. Learn about the two main types of sleep apnea and hear from experts as they present the latest research at the Sleep and Breathing conference (Marseille, 2019).

Hereditary ATTR amyloidosis

Hereditary ATTR amyloidosis

Explore the pathophysiology, epidemiology and multi-system symptoms associated with hereditary ATTR amyloidosis, as well as how to achieve an early and accurate diagnosis.

Load more

Related Content

Advisory information

contraindications

4 CONTRAINDICATIONS Do not use in patients with anuria, hypersensitivity to other sulfonamide-derived drugs, or hypersensitivity to any component of this product.

Do not coadminister aliskiren with Exforge HCT in patients with diabetes [see Drug Interactions (7)].

Anuria (4) Hypersensitivity to sulfonamide-derived drugs (4) Known hypersensitivity to any component (4) Do not coadminister aliskiren with Exforge HCT in patients with diabetes (4)

Adverse reactions

6 ADVERSE REACTIONS Most common adverse events (?2 % incidence) are dizziness, peripheral edema, headache, dyspepsia, fatigue, muscle spasms, back pain, nausea and nasopharyngitis.

(6.1) To report SUSPECTED ADVERSE REACTIONS, contact Novartis Pharmaceuticals Corporation at 1-888-669-6682 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

6.1 Clinical Trials Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug can not be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in clinical practice.

In the controlled trial of Exforge HCT, where only the maximum dose (10/320/25 mg) was evaluated, safety data were obtained in 582 patients with hypertension.

Adverse reactions have generally been mild and transient in nature and have only infrequently required discontinuation of therapy.

The overall frequency of adverse reactions was similar between men and women, younger (<65 years) and older (>65 years) patients, and black and white patients.

In the active controlled clinical trial, discontinuation because of adverse events occurred in 4.0 % of patients treated with Exforge HCT 10/320/25 mg compared to 2.9 % of patients treated with valsartan/HCTZ 320/25 mg, 1.6 % of patients treated with amlodipine/valsartan 10/320 mg, and 3.4 % of patients treated with HCTZ/amlodipine 25/10 mg.

The most common reasons for discontinuation of therapy with Exforge HCT were dizziness (1.0 %) and hypotension (0.7 %).

The most frequent adverse events that occurred in the active controlled clinical trial in at least 2 % of patients treated with Exforge HCT are presented in the following table.

Preferred Term Aml/Val/HCTZ 10/320/25 mg N=582 n (%) Val/HCTZ 320/25 mg N=559 n (%) Aml/Val 10/320 mg N=566 n (%) HCTZ/Aml 25/10 mg N=561 n (%) Dizziness 48 (8.2) 40 (7.2) 14 (2.5) 23 (4.1) Edema 38 (6.5) 8 (1.4) 65 (11.5) 63 (11.2) Headache 30 (5.2) 31 (5.5) 30 (5.3) 40 (7.1) Dyspepsia 13 (2.2) 5 (0.9) 6 (1.1) 2 (0.4) Fatigue 13 (2.2) 15 (2.7) 12 (2.1) 8 (1.4) Muscle spasms 13 (2.2) 7 (1.3) 7 (1.2) 5 (0.9) Back pain 12 (2.1) 13 (2.3) 5 (0.9) 12 (2.1) Nausea 12 (2.1) 7 (1.3) 10 (1.8) 12 (2.1) Nasopharyngitis 12 (2.1) 13 (2.3) 13 (2.3) 12 (2.1) Orthostatic events (orthostatic hypotension and postural dizziness) were seen in 0.5 % of patients.

Other adverse reactions that occurred in clinical trials with Exforge HCT (>0.2 %) are listed below.

It can not be determined whether these events were causally related to Exforge HCT. Cardiac Disorders: tachycardia Ear and Labyrinth Disorders: vertigo, tinnitus Eye Disorders: vision blurred Gastrointestinal Disorders: diarrhea, abdominal pain upper, vomiting, abdominal pain, toothache, dry mouth, gastritis, hemorrhoids General Disorders and Administration Site Conditions: asthenia, noncardiac chest pain, chills, malaise Infections and Infestations: upper respiratory tract infection, bronchitis, influenza, pharyngitis, tooth abscess, gastroenteritis viral, respiratory tract infection, rhinitis, urinary tract infection Injury, Poisoning and Procedural Complications: back injury, contusion, joint sprain, procedural pain Investigations: blood uric acid increased

blood creatine phosphokinase increased, weight decreased Metabolism and Nutrition Disorders: hypokalemia, diabetes mellitus, hyperlipidemia, hyponatremia Musculoskeletal and Connective Tissue Disorders: pain in extremity, arthralgia, musculoskeletal pain, muscular weakness, musculoskeletal weakness, musculoskeletal stiffness, joint swelling, neck pain, osteoarthritis, tendonitis Nervous System Disorders: paresthesia, somnolence, syncope, carpal tunnel syndrome, disturbance in attention, dizziness postural, dysgeusia, head discomfort, lethargy, sinus headache, tremor Psychiatric Disorders: anxiety, depression, insomnia Renal and Urinary Disorders: pollakiuria Reproductive System and Breast

Disorders: erectile dysfunction

Respiratory, Thoracic and Mediastinal Disorders: dyspnea, nasal congestion, cough, pharyngolaryngeal pain Skin and Subcutaneous Tissue Disorders: pruritus, hyperhidrosis, night sweats, rash Vascular Disorders: hypotension Isolated cases of the following clinically notable adverse reactions were also observed in clinical trials: anorexia, constipation, dehydration, dysuria, increased appetite, viral infection.

Amlodipine Amlodipine has been evaluated for safety in more than 11000 patients in US and foreign clinical trials.

Other adverse reactions not listed above that have been reported in <1 % but >0.1 % of patients in controlled clinical trials or under conditions of open trials or marketing experience where a causal relationship is uncertain were: Cardiovascular: arrhythmia (including ventricular tachycardia and atrial fibrillation), bradycardia, chest pain, peripheral ischemia, syncope, postural hypotension, vasculitis Central and Peripheral Nervous

System: neuropathy peripheral, tremor Gastrointestinal: anorexia, dysphagia, pancreatitis, gingival hyperplasia General: allergic reaction, hot flushes, malaise, rigors, weight gain Musculoskeletal System: arthrosis, muscle cramps Psychiatric: sexual dysfunction (male and female), nervousness, abnormal dreams, depersonalization Skin and Appendages: angioedema, erythema multiforme, rash erythematous, rash maculopapular Special Senses: abnormal vision, conjunctivitis, diplopia, eye pain, tinnitus Urinary System: micturition frequency, micturition disorder, nocturia Autonomic Nervous System: sweating increased Metabolic and Nutritional: hyperglycemia, thirst Hemopoietic: leukopenia, purpura, thrombocytopenia Other adverse reactions reported with amlodipine at a frequency of?

0.1 % of patients include: cardiac failure, pulse irregularity, extrasystoles, skin discoloration, urticaria, skin dryness, alopecia, dermatitis, muscle weakness, twitching, ataxia, hypertonia, migraine, cold and clammy skin, apathy, agitation, amnesia, gastritis, increased appetite, loose stools, rhinitis, dysuria, polyuria, parosmia, taste perversion, abnormal visual accommodation, and xerophthalmia.

Other reactions occurred sporadically and can not be distinguished from medications or concurrent disease states such as myocardial infarction and angina.

Adverse reactions reported for amlodipine for indications other than hypertension may be found in its full prescribing information.

Valsartan Valsartan has been evaluated for safety in more than 4000 hypertensive patients in clinical trials.

In trials in which valsartan was compared to an ACE inhibitor with or without placebo, the incidence of dry cough was significantly greater in the ACE inhibitor group (7.9 %) than in the groups who received valsartan (2.6 %) or placebo (1.5 %).

In a 129-patient trial limited to patients who had dry cough when they had previously received ACE inhibitors, the incidences of cough in patients who received valsartan, HCTZ, or lisinopril were 20 %, 19 %, and 69 % respectively (p <0.001).

Other adverse reactions, not listed above, occurring in >0.2 % of patients in controlled clinical trials with valsartan are: Digestive: flatulence Respiratory: sinusitis, pharyngitis Urogenital: impotence Adverse reactions reported for valsartan for indications other than hypertension may be found in the prescribing information for Diovan.

Hydrochlorothiazide Other adverse reactions not listed above that have been reported with hydrochlorothiazide, without regard to causality, are listed below: Body as a Whole: weakness Digestive: pancreatitis, jaundice (intrahepatic cholestatic jaundice), sialadenitis, cramping, gastric irritation Hematologic: aplastic anemia, agranulocytosis, hemolytic anemia Hypersensitivity: photosensitivity, urticaria, necrotizing angiitis (vasculitis and cutaneous vasculitis), fever, respiratory distress including pneumonitis and pulmonary edema, anaphylactic reactions Metabolic: glycosuria, hyperuricemia Nervous

System/Psychiatric: restlessness Renal: renal failure, renal dysfunction, interstitial nephritis Skin: erythema multiforme including Stevens-Johnson syndrome, exfoliative dermatitis including toxic epidermal necrolysis Special Senses: transient blurred vision, xanthopsia.

Clinical Laboratory Test Findings Clinical laboratory test findings for Exforge HCT were obtained in a controlled trial of Exforge HCT administered at the maximal dose of 10/320/25 mg compared to maximal doses of dual therapies, i.e., valsartan/HCTZ 320/25 mg, amlodipine/valsartan 10/320 mg, and HCTZ/amlodipine 25/10 mg.

Findings for the components of Exforge HCT were obtained from other trials.

Creatinine: In hypertensive patients, greater than 50 % increases in creatinine occurred in 2.1 % of Exforge HCT patients compared to 2.4 % of valsartan/HCTZ patients, 0.7 % of amlodipine/valsartan patients, and 1.8 % of HCTZ/amlodipine patients.

In heart failure patients, greater than 50 % increases in creatinine were observed in 3.9 % of valsartan-treated patients compared to 0.9 % of placebo-treated patients.

In post-myocardial infarction patients, doubling of serum creatinine was observed in 4.2 % of valsartan-treated patients and 3.4 % of captopril-treated patients.

Liver Function Tests: Occasional elevations (greater than 150 %) of liver chemistries occurred in Exforge HCT-treated patients.

Blood Urea Nitrogen (BUN): In hypertensive patients, greater than 50 % increases in BUN were observed in 30 % of Exforge HCT-treated patients compared to 29 % of valsartan/HCTZ patients, 15.8 % of amlodipine/valsartan patients, and 18.5 % of HCTZ/amlodipine patients.

The majority of BUN values remained within normal limits.

In heart failure patients, greater than 50 % increases in BUN were observed in 17 % of valsartan-treated patients compared to 6 % of placebo-treated patients.

Serum Electrolytes (Potassium): In hypertensive patients, greater than 20 % decreases in serum potassium were observed in 6.5 % of Exforge HCT-treated patients compared to 3.3 % of valsartan/HCTZ patients, 0.4 % of amlodipine/valsartan patients, and 19.3 % of HCTZ/amlodipine patients.

Greater than 20 % increases in potassium were observed in 3.5 % of Exforge HCT-treated patients compared to 2.4 % of valsartan/HCTZ patients, 6.2 % of amlodipine/valsartan patients, and 2.2 % of HCTZ/amlodipine patients.

In heart failure patients, greater than 20 % increases in serum potassium were observed in 10 % of valsartan-treated patients compared to 5.1 % of placebo-treated patients [see Warnings and Precautions (5.5)].

Neutropenia: Neutropenia (<1500/L) was observed in 1.9 % of patients treated with valsartan and 0.8 % of patients treated with placebo.

6.2 Postmarketing Experience The following additional adverse reactions have been reported in postmarketing experience.

Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Amlodipine With amlodipine, gynecomastia has been reported infrequently and a causal relationship is uncertain.

Jaundice and hepatic enzyme elevations (mostly consistent with cholestasis or hepatitis), in some cases severe enough to require hospitalization, have been reported in association with use of amlodipine.

Valsartan The following additional adverse reactions have been reported in postmarketing experience with valsartan or valsartan/hydrochlorothiazide: Blood and Lymphatic: Decrease in hemoglobin, decrease in hematocrit, neutropenia Hypersensitivity: There are rare reports of angioedema.

Some of these patients previously experienced angioedema with other drugs including ACE inhibitors.

Exforge HCT should not be re-administered to patients who have had angioedema.

Digestive: Elevated liver enzymes and very rare reports of hepatitis Renal: Impaired renal function, renal failure Clinical Laboratory Tests: Hyperkalemia Dermatologic: Alopecia, bullous dermatitis

Vascular: Vasculitis Nervous System: Syncope Rare cases of rhabdomyolysis have been reported in patients receiving angiotensin II receptor blockers.

Hydrochlorothiazide The following additional adverse reactions have been reported in postmarketing experience with hydrochlorothiazide: Acute renal failure, renal disorder, aplastic anemia, erythema multiforme, pyrexia, muscle spasm, asthenia, acute angle-closure glaucoma, bone marrow failure, worsening of diabetes control, hypokalemia, blood lipids increased, hyponatremia, hypomagnesemia, hypercalcemia, hypochloremic alkalosis, impotence, visual impairment.

Pathological changes in the parathyroid gland of patients with hypercalcemia and hypophosphatemia have been observed in a few patients on prolonged thiazide therapy.

If hypercalcemia occurs, further diagnostic evaluation is necessary.

Usage information

Dosing and administration

2 DOSAGE AND ADMINISTRATION Dose once-daily.

Titrate up to a maximum dose of 10/320/25 mg Exforge HCT may be used as add-on/switch therapy for patients not adequately controlled on any two of the following antihypertensive classes: calcium channel blockers, angiotensin receptor blockers, and diuretics.

Exforge HCT may be substituted for its individually titrated components (2) 2.1 General Considerations Dose once-daily.

The dosage may be increased after 2 weeks of therapy.

The full blood pressure lowering effect was achieved 2 weeks after being on the maximal dose of Exforge HCT.

The maximum recommended dose of Exforge HCT is 10/320/25 mg.

2.2 Add-on/Switch Therapy Exforge HCT may be used for patients not adequately controlled on any 2 of the following antihypertensive classes: calcium channel blockers, angiotensin receptor blockers, and diuretics.

A patient who experiences dose-limiting adverse reactions to an individual component while on any dual combination of the components of

Exforge HCT may be switched to Exforge HCT containing a lower dose of that component to achieve similar blood pressure reductions.

2.3 Replacement Therapy Exforge HCT may be substituted for the individually titrated components.

2.4 Use with Other Antihypertensive Drugs Exforge HCT may be administered with other antihypertensive agents.

Use in special populations

8 USE IN SPECIFIC POPULATIONS Nursing Mothers: Avoid use while nursing - discontinue either nursing or drug (8.3) Geriatric Patients: Not recommended for initial therapy (8.5) Hepatic Impairment: Not recommended for initial therapy (8.7) 8.1 Pregnancy Pregnancy Category D Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death.

Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations.

Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death.

When pregnancy is detected, discontinue Exforge HCT as soon as possible.

These adverse outcomes are usually associated with use of these drugs in the second and third trimesters of pregnancy.

Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents.

Appropriate management of maternal hypertension during pregnancy is important to optimize outcomes for both mother and fetus.

In the unusual case that there is no appropriate alternative to therapy with drugs affecting the renin-angiotensin system for a particular patient, apprise the mother of the potential risk to the fetus.

Perform serial ultrasound examinations to assess the intra-amniotic environment.

If oligohydramnios is observed, discontinue Exforge HCT, unless it is considered lifesaving for the mother.

Fetal testing may be appropriate, based on the week of pregnancy.

Patients and physicians should be aware, however, that oligohydramnios may not appear until after the fetus has sustained irreversible injury.

Closely observe infants with histories of in utero exposure to Exforge HCT for hypotension, oliguria, and hyperkalemia [see Use in Specific Populations (8.4)].

Hydrochlorothiazide Thiazides can cross the placenta, and concentrations reached in the umbilical vein approach those in the maternal plasma.

Hydrochlorothiazide, like other diuretics, can cause placental hypoperfusion.

It accumulates in the amniotic fluid, with required concentrations up to 19 times higher than in umbilical vein plasma.

Use of thiazides during pregnancy is associated with a risk of fetal or neonatal jaundice of thrombocytopenia.

Since they do not prevent or alter the course of EPH (Edema, Proteinuria, Hypertension) gestosis (pre-eclampsia), these drugs should not be used to treat hypertension in pregnant women.

The use of hydrochlorothiazide for other indications (e.g., heart disease) in pregnancy should be avoided.

8.3 Nursing Mothers It is not known whether amlodipine and valsartan are excreted in human milk, but thiazides are excreted in human milk and valsartan is excreted in rat milk.

Because of the potential for adverse effects on the nursing infant, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

8.4 Pediatric Use The safety and effectiveness of Exforge HCT in pediatric patients have not been established.

Neonates with a history of in utero exposure to Exforge HCT: If oliguria or hypotension occurs, direct attention toward support of blood pressure and renal perfusion.

Exchange transfusions or dialysis may be required as a means of reversing hypotension and/or substituting for disordered renal function.

8.5 Geriatric Use Amlodipine: Clinical studies of amlodipine besylate tablets did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.

Other reported clinical experience has not identified differences in responses between the elderly and younger patients.

In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy.

Elderly patients have decreased clearance of amlodipine with a resulting increase of AUC of approximately 40 % to 60 % [see Clinical Pharmacology (12.3)].

The recommended starting dose of amlodipine 2.5 mg is not an available strength with Exforge HCT [see Clinical Studies (14)].

8.6 Renal Impairment Safety and effectiveness of Exforge HCT in patients with severe renal impairment (CrCl <30 mL/min) have not been established.

No dose adjustment is required in patients with mild (CrCl 60 to 90 mL/min) or moderate (CrCl 30 to 60 mL/min) renal impairment.

8.7 Hepatic Impairment Amlodipine Exposure to amlodipine is increased in patients with hepatic insufficiency, The recommended initial dose of amlodipine in patients with hepatic impairment is 2.5 mg, which is not an available strength with Exforge HCT [see Clinical Pharmacology (12.3)].

Valsartan No dose adjustment is necessary for patients with mild-to-moderate disease.

No dosing recommendations can be provided for patients with severe liver disease.

Hydrochlorothiazide Minor alterations of fluid and electrolyte balance may precipitate hepatic coma in patients with impaired hepatic function or progressive liver disease.

Pregnancy and lactation
8.3 Nursing Mothers It is not known whether amlodipine and valsartan are excreted in human milk, but thiazides are excreted in human milk and valsartan is excreted in rat milk. Because of the potential for adverse effects on the nursing infant, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

Interactions

7 DRUG INTERACTIONS No drug interaction studies have been conducted with Exforge HCT and other drugs, although studies have been conducted with the individual components.

A pharmacokinetic drug-drug interaction study has been conducted to address the potential for pharmacokinetic interaction between the triple combination, Exforge HCT, and the corresponding 3 double combinations.

No clinically relevant interaction was observed.

Amlodipine Impact of other Drugs on Amlodipine CYP3A Inhibitors Co-administration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction.

Monitor for symptoms of hypotension and edema when amlodipine is co-administered with CYP3A inhibitors to determine the need for dose adjustment [see Clinical Pharmacology (12.3)].

CYP3A Inducers No information is available on the quantitative effects of CYP3A inducers on amlodipine.

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers.

Sildenafil Monitor for hypotension when sildenafil is co-administered with amlodipine [see Clinical Pharmacology (12.2)].

Impact of Amlodipine on other Drugs Simvastatin Co-administration of simvastatin with amlodipine increases the systemic exposure of simvastatin.

Limit the dose of simvastatin in patients on amlodipine to 20 mg daily [see Clinical Pharmacology (12.3)].

Immunosuppressants Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered.

Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended and adjust the dose when appropriate [see Clinical Pharmacology (12.3)].

Valsartan No clinically significant pharmacokinetic interactions were observed when valsartan was coadministered with amlodipine, atenolol, cimetidine, digoxin, furosemide, glyburide, hydrochlorothiazide, or indomethacin.

The valsartan-atenolol combination was more antihypertensive than either component, but it did not lower the heart rate more than atenolol alone.

In vitro metabolism studies have indicated that CYP450 mediated drug interaction between valsartan and coadministered drugs are unlikely because of the low extent of metabolism [see Pharmacokinetics - Valsartan, (12.3)].

Coadministration of valsartan and warfarin did not change the pharmacokinetics of valsartan or the time-course of the anticoagulant properties of warfarin.

Potassium: Concomitant use of valsartan with other agents that block the renin-angiotensin system, potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, salt substitutes containing potassium or other drugs that may increase potassium levels (e.g., heparin) may lead to increases in serum potassium and in heart failure patients to increases in serum creatinine.

If co-medication is considered necessary, monitoring of serum potassium is advisable.

Non-Steroidal Anti-Inflammatory Agents including

Selective

Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors): In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists, including valsartan, may result in deterioration of renal function, including possible acute renal failure.

These effects are usually reversible.

Monitor renal function periodically in patients receiving valsartan and NSAID therapy.

The antihypertensive effect of angiotensin II receptor antagonists, including valsartan, may be attenuated by NSAIDs including selective COX-2 inhibitors.

Dual Blockade of the Renin-Angiotensin System (RAS): Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy.

Most patients receiving the combination of two RAS inhibitors do not obtain any additional benefit compared to monotherapy.

In general, avoid combined use of RAS inhibitors.

Closely monitor blood pressure, renal function, and electrolytes in patients on Exforge HCT and other agents that affect the RAS. Do not coadminister aliskiren with Exforge HCT in patients with diabetes.

Avoid use of aliskiren with Exforge HCT in patients with renal impairment (GFR <60 mL/min).

Valsartan - Hydrochlorothiazide Lithium: Increases in serum lithium concentrations and lithium toxicity have been reported during concomitant administration of lithium with angiotensin II receptor antagonists or thiazides.

Monitor lithium levels in patients taking Exforge HCT. Hydrochlorothiazide When administered concurrently the following drugs may interact with thiazide diuretics: Antidiabetic drugs (oral agents and insulin): Dosage adjustment of the antidiabetic drug may be required.

Non-steroidal anti-inflammatory drugs (NSAIDs and COX-2 selective inhibitors): When Exforge HCT and nonsteroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of diuretic is obtained.

Carbamazepine: May lead to symptomatic hyponatremia.

Ion exchange resins: Staggering the dosage of hydrochlorothiazide and ion exchange resins (e.g., cholestyramine, colestipol) such that hydrochlorothiazide is administered at least 4 hours before or 4 to 6 hours after the administration of resins would potentially minimize the interaction [see Clinical Pharmacology (12.3)].

Cyclosporine: Concomitant treatment with cyclosporine may increase the risk of hyperuricemia and gout-type complications.

If simvastatin is coadministered with amlodipine, do not exceed doses greater than 20 mg daily of simvastatin (7) Antidiabetic drugs: Dosage adjustment of antidiabetic may be required (7) Cholestyramine and colestipol: Reduced absorption of thiazides (12.3) Lithium: Increased risk of lithium toxicity.

Monitor serum lithium concentrations during concurrent use.

(7) NSAID use may lead to increased risk of renal impairment and loss of anti-hypertensive effect (7) Dual inhibition of the renin-angiotensin system: Increased risk of renal impairment, hypotension, and hyperkalemia (7)

More information

Category Value
Authorisation number NDA022314
Agency product number 0J48LPH2TH
Orphan designation No
Product NDC 0078-0559,0078-0561,0078-0562,0078-0563,0078-0560
Date Last Revised 28-07-2015
Type HUMAN PRESCRIPTION DRUG
RXCUI 848131
Marketing authorisation holder Novartis Pharmaceuticals Corporation
Warnings

WARNING:

FETAL TOXICITY When pregnancy is detected, discontinue Exforge HCT as soon as possible.

(5.1) Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus.

(5.1) WARNING:

FETAL TOXICITY See full prescribing information for complete boxed warning.

When pregnancy is detected, discontinue Exforge HCT as soon as possible.

(5.1) Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus.

(5.1)